Glenmark

Glenmark Pharmaceuticals has introduced a generic version of Sodium Phosphates Injection in the United States, strengthening its foothold in the regulated injectable segment. The product, launched following approval from the US Food and Drug Administration, targets hospital and institutional markets where demand for cost-effective alternatives remains strong. The move reflects Glenmark’s strategy to deepen its presence in high-value, complex generics while diversifying revenue streams beyond oral solids. As pricing pressures persist across the U.S.

Glenmark Pharmaceuticals has launched a new triple therapy treatment for Chronic Obstructive Pulmonary Disease (COPD) in India, targeting patients with moderate to severe respiratory conditions. The innovative therapy combines three active components in a single inhaler, offering enhanced symptom management, improved lung function, and simplified treatment adherence. This launch underscores Glenmark’s commitment to addressing chronic respiratory illnesses and expanding its presence in India’s growing specialty therapeutics segment.

Indian pharmaceutical major Glenmark Pharmaceuticals has received critical observations from the United States Food and Drug Administration (USFDA) following an inspection of its Baddi facility in Himachal Pradesh. The US regulator, after a routine audit, identified multiple lapses in the plant’s manufacturing practices, issuing a Form 483 with seven key observations. While the company has yet to receive any import restrictions or warning letters, the findings underscore the growing scrutiny faced by Indian drugmakers exporting to the United States.